ACELYRIN is investing in, developing and commercializing life-changing drug therapies. ACELYRIN’s approach is to identify and develop therapeutics through efficient and ongoing collaborations with academia, big-pharma and early-stage start-ups to get the right expertise throughout the entire process. ACELYRIN’s lead candidate is izokibep, a monoclonal antibody mimetic to inhibit interleukin-17A (IL-17A) with high potency and tissue penetrance. Currently, ACELYRIN is actively investigating the potential of izokibep in diseases with perturbed IL-17A signaling. This includes Phase 2/3 trials for inflammatory diseases of the eye (Uveitis) and skin (Psoriatic Arthritis).
Claim company profile to post jobs directly on this page and this website.